SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: POST HOC ANALYSIS OF LIBERTY-UC STUDY AND LIBERTY-CD STUDY

Silvio Danese  ¹     Jean-Frédéric Colombel  ²     Steve Hanauer  ³     William J. Sandborn  ⁴     Bruce E. Sands  ⁴     Stefan Schreiber  ⁵     Sang Joon Lee  ⁶     Sung Hyun Kim  ⁶     Yun Ju Bae  ⁶     Sun Hee Lee  ⁶     Seul Gi Lee  ⁶     JoonHo Lee  ⁶     Jong Min Kim  ⁶     SIYOUNG YANG  ⁶     Jimin Lee  ⁶     Gahee Park  ⁶     Juhyun Lee  ^6    
1 IRCCS San Raffaele Scientific Institute, Milan, Italy
² Icahn School of Medicine at Mount Sinai, New York, United States
³ Northwestern University/ Feinberg School of Medicine, Chicago, IL, United States
⁴ University of California San Diego, La Jolla, United States
⁵ University Hospital Schleswig-Holstein, Kiel, Germany
⁶ Celltrion, Inc, Incheon, Korea, Republic of

Topic
IBD

Session
Meet the giants at the poster (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)